ResMed Inc. (NYSE:RMD) Given Consensus Rating of "Hold" by Brokerages

Key Points

• Analysts have a consensus “Hold” rating on ResMed, with nine holds and seven buys among 16 covering firms. The average 12-month price target is $246.25, though targets range from $225 to $300.
• ResMed reported a quarterly earnings beat, with EPS of $2.95 versus the $2.89 consensus estimate. Revenue rose 8.6% year over year to $1.46 billion, while net margin reached 27.44% and return on equity was 25.35%.
• Shares opened at $223.77, down 0.1%, amid mixed analyst sentiment and some insider selling. Director Peter Farrell sold $1.8 million of stock under a pre-arranged Rule 10b5-1 plan, reducing the transaction’s signaling value.

Shares of ResMed Inc. (NYSE:RMD - Get Free Report) have received an average recommendation of "Hold" from the sixteen research firms that are covering the company, MarketBeat Ratings reports. Nine research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $246.25.

Several brokerages have recently weighed in on RMD. Citigroup reissued a "neutral" rating and set a $235.00 price objective (down from $270.00) on shares of ResMed in a report on Sunday, July 12th. Evercore set a $255.00 target price on ResMed and gave the company an "outperform" rating in a research note on Monday, April 13th. UBS Group reaffirmed a "buy" rating and issued a $300.00 target price on shares of ResMed in a research report on Tuesday, July 21st. The Goldman Sachs Group reiterated a "buy" rating on shares of ResMed in a research note on Wednesday, July 1st. Finally, Robert W. Baird set a $225.00 price target on shares of ResMed in a report on Friday, May 1st.

Key Stories Impacting ResMed

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: ResMed reported fiscal Q4 earnings of $2.95 per share, exceeding the approximately $2.89–$2.90 analyst consensus and rising from $2.55 a year earlier. Revenue reached $1.46 billion, in line with estimates and up 8.6% year over year, supporting the company’s growth narrative. ResMed Q4 Earnings and Revenues Top Estimates
• Positive Sentiment: The company also announced a dividend increase alongside strong fourth-quarter and full-year fiscal 2026 results, potentially improving the stock’s appeal to income-oriented investors. ResMed Reports Strong Q4 Results and Dividend Increase
• Positive Sentiment: Management’s earnings call follows a quarter with a 27.44% net margin and 25.35% return on equity, indicating continued profitability and operating strength. ResMed Q4 2026 Earnings Call Transcript
• Neutral Sentiment: Analyst views on ResMed remain mixed, which may be limiting the market’s reaction despite the earnings beat. Earlier previews also highlighted tariff, inflation and hospital-spending risks facing medtech companies. Analysts Have Conflicting Sentiments on ResMed
• Negative Sentiment: Director Peter C. Farrell sold 8,000 shares worth $1.8 million. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, reducing its signaling value, but it may still add modest short-term selling pressure. SEC Insider Trading Filing

ResMed Stock Down 0.1%

Shares of RMD opened at $223.77 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.33 and a current ratio of 3.01. The company has a 50-day simple moving average of $200.06 and a 200-day simple moving average of $222.30. ResMed has a 52 week low of $180.26 and a 52 week high of $293.81. The firm has a market capitalization of $32.46 billion, a P/E ratio of 21.58, a P/E/G ratio of 1.36 and a beta of 0.76.

ResMed (NYSE:RMD - Get Free Report) last released its earnings results on Thursday, August 6th. The medical equipment provider reported $2.95 earnings per share for the quarter, topping analysts' consensus estimates of $2.89 by $0.06. ResMed had a return on equity of 25.35% and a net margin of 27.44%.The business had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.46 billion. During the same period last year, the business earned $2.55 earnings per share. The firm's revenue for the quarter was up 8.6% compared to the same quarter last year. On average, equities research analysts expect that ResMed will post 11.14 earnings per share for the current year.

Insider Transactions at ResMed

In other news, Director Peter C. Farrell sold 8,000 shares of ResMed stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $225.00, for a total transaction of $1,800,000.00. Following the sale, the director directly owned 52,773 shares in the company, valued at approximately $11,873,925. The trade was a 13.16% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Michael J. Farrell sold 4,991 shares of the company's stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $218.55, for a total transaction of $1,090,783.05. Following the completion of the sale, the chief executive officer directly owned 466,223 shares in the company, valued at approximately $101,893,036.65. The trade was a 1.06% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 17,982 shares of company stock valued at $3,858,837 over the last ninety days. 0.65% of the stock is owned by insiders.

Institutional Investors Weigh In On ResMed

Several large investors have recently modified their holdings of RMD. State Street Corp lifted its position in shares of ResMed by 1.2% during the 4th quarter. State Street Corp now owns 6,625,408 shares of the medical equipment provider's stock worth $1,595,862,000 after buying an additional 76,244 shares during the period. Bank of New York Mellon Corp grew its position in ResMed by 0.7% in the first quarter. Bank of New York Mellon Corp now owns 4,925,386 shares of the medical equipment provider's stock valued at $1,105,651,000 after acquiring an additional 34,732 shares during the period. Geode Capital Management LLC boosted its stake in shares of ResMed by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 4,302,906 shares of the medical equipment provider's stock valued at $1,032,877,000 after purchasing an additional 51,218 shares in the last quarter. Morgan Stanley lifted its holdings in ResMed by 25.0% during the 4th quarter. Morgan Stanley now owns 2,891,697 shares of the medical equipment provider's stock valued at $696,523,000 after purchasing an additional 578,559 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in shares of ResMed by 5.2% during the fourth quarter. Northern Trust Corp now owns 1,785,384 shares of the medical equipment provider's stock worth $430,045,000 after buying an additional 87,502 shares in the last quarter. 54.98% of the stock is currently owned by institutional investors.

ResMed Company Profile

ResMed NYSE: RMD is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed's product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source